MARKET

MDGL

MDGL

Madrigal Pharmac
NASDAQ
308.59
+21.07
+7.33%
After Hours: 309.00 +0.41 +0.13% 19:23 07/09 EDT
OPEN
290.61
PREV CLOSE
287.52
HIGH
310.00
LOW
290.61
VOLUME
352.03K
TURNOVER
--
52 WEEK HIGH
377.46
52 WEEK LOW
200.63
MARKET CAP
6.85B
P/E (TTM)
-17.1027
1D
5D
1M
3M
1Y
5Y
1D
Loss-Making Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Expected To Breakeven In The Medium-Term
Simply Wall St · 1d ago
MDGL Makes Notable Cross Below Critical Moving Average
NASDAQ · 2d ago
Weekly Report: what happened at MDGL last week (0630-0704)?
Weekly Report · 2d ago
Citizens JMP Remains a Buy on Madrigal Pharmaceuticals (MDGL)
TipRanks · 07/02 11:30
Weekly Report: what happened at MDGL last week (0623-0627)?
Weekly Report · 06/30 09:23
Short Report: Rocket Companies short interest at record high
TipRanks · 06/29 18:05
Altimmune: Deciphering The MASH Crash (Rating Upgrade)
Seeking Alpha · 06/26 20:30
Madrigal, Viking among notable gainers after Altimmune’s MASH setback
Seeking Alpha · 06/26 19:42
More
About MDGL
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).

Webull offers Madrigal Pharmaceuticals Inc stock information, including NASDAQ: MDGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDGL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MDGL stock methods without spending real money on the virtual paper trading platform.